YNIOS PHARMA is leading a Critical Care preclinical program to demonstrate its effectiveness in modulating acute systemic inflammatory responses, protecting vital organs and promoting faster patient recovery.

These acute systemic inflammatory responses can also develop into different situations such as Septic Shock, Acute Ischemic Stroke, Acute Myocardial Infarction and organ transplantation.

YNIOS PHARMA business model is to create revenues from out-licensing. The current strategy aims at early out-licensing the assets under development when Phase I/II studies have demonstrated the safety and efficacy of the compound.

YNIOS PHARMA is a biotech founded in March 2022 by Philippe Van Wesepoel and Jean François Plucker, the same founders of biotech OLYS Pharma  which develops topical neuro-cutaneous treatments. *

* Diabetic Peripheral Neuropathic Pain – Neuralgia of the trigeminocervical complex (Migraine) – Low back pain – Osteoarthritis – Irritable Bowel Syndrome – Bladder Pain Syndrome


JF. Plucker
JF. PluckerCo-founder & COO
Partner of an intellectual property firm in Brussels, Jean François worked for clients in many countries, before moving to the United States where he specialized in technology transfers between university or federal laboratories and private industrial companies. Combining scientific and economic logics became its strength, where the two logics usually clash. He puts his international experience at the service of humanly useful and economically promising projects. Co-founder of YNIOS PHARMA, he brings a seasoned experience in management, international trade and intellectual property in the development of the Start-Up.
Ph. Van Wesepoel
Ph. Van WesepoelCo-founder & CSO
With a scientific background and an MBA, Philippe Van Wesepoel has experience in different therapeutic areas of the pharmaceutical industry demonstrating both his practicality and his scientific rigor. He is passionate about cellular physiology, sensing and signaling channels, and their evolution over time and across species, on which he relies to develop effective and well-tolerated treatments, both by restoring the physiological innate immune capacity of cells and respecting homeostasis.


The founders are the Associate Directors of the company. They combine extensive experience in management, international business development, intellectual property, research and innovation, and partnership strategies.